Indication
Parkinson's Disease
The Parkinson's Disease pipeline: 125 tracked drugs, 17 approved for this indication.
17 approved / phase 415 Phase 33 Phase 2/336 Phase 213 Phase 1/236 Phase 15 preclinical / unstaged
Compare the share prices of listed companies in Parkinson's Disease →
Total attributable cost
$25.4B
$24,439/patient
Drug spend
$4.1B
$3,988/patient
16% of total cost is drugs
All severities (2017 MEPS-anchored estimate) · US